Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa

NCT02216071 is registered in ClinicalTrials.gov with Exela Pharma Sciences, LLC. as lead sponsor.

NCT NCT02216071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02216071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa
Lead sponsor
Exela Pharma Sciences, LLC.
Phase
Phase 3
Overall status
Completed
Start date
July 20, 2014
Completion date
August 11, 2015
Enrollment
499 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

acute otitis externa